Effects of Oplusituzumab/Ointuzumab (Besponsa)

An important clinical trial of oxetuzumab/oxintuzumab (Besponsa) is studying the drug's efficacy in adultsB-cell acute lymphoblastic leukemia (B-ALL). The trial results showed that more patients in the o plus itutuzumab/ointuzumab treatment group achieved complete remission (CR) and durable remission, and compared with the control group, the relapse-free survival (RFS) of the treatment group was significantly longer. It is worth noting that the therapeutic effect of oplusituzumab/ointuzumab is not only manifested in the short term, but can also last for a long time. In some patients, durable remission remains after treatment, providing patients with a longer chance of survival and better quality of life.